Does the future of myeloma treatment belong to trispecific antibodies?
Impossibile aggiungere al carrello
Rimozione dalla Lista desideri non riuscita.
Non è stato possibile aggiungere il titolo alla Libreria
Non è stato possibile seguire il Podcast
Esecuzione del comando Non seguire più non riuscita
Does the future of myeloma treatment belong to trispecific antibodies?
-
Letto da:
-
Di:
A proposito di questo titolo
In this SOHO Insider podcast, Saad Usmani, MD, chief of the myeloma service at Memorial Sloan Kettering Cancer Center, and Niels W C J van de Donk, MD, professor of hematology at Amsterdam UMC, provide an overview of immunotherapies. They discuss bispecific and trispecific antibodies, including early data from the trispecifics and the therapies moving into the frontline setting in multiple myeloma treatment.
The pair spoke about the novel trispecific antibody JNJ-5322 that targets BCMA and GPRC5D via T-cell redirection and ISB 2001, an investigational trispecific antibody that received FDA fast track designation earlier in 2025.
“The future looks bright for the trispecifics,” Dr. van de Donk said. “We are also looking at combination strategies now in that patients with earlier, lines of therapy, less prior lines of therapy, we are even testing the trispecific now in combination with dara in newly diagnosed patients and the future hopefully again challenging transplant which is still a key component in Europe for the newly diagnosed myeloma patient.
Listen to more SOHO Insider podcasts.